Aegis Wealth Management LLC Buys New Shares in GSK plc (NYSE:GSK)

Aegis Wealth Management LLC acquired a new stake in shares of GSK plc (NYSE:GSK - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 8,459 shares of the pharmaceutical company's stock, valued at approximately $286,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Probity Advisors Inc. grew its position in GSK by 58.8% during the fourth quarter. Probity Advisors Inc. now owns 15,120 shares of the pharmaceutical company's stock valued at $511,000 after purchasing an additional 5,599 shares in the last quarter. BridgePort Financial Solutions LLC acquired a new stake in GSK in the fourth quarter valued at approximately $310,000. Total Wealth Planning & Management Inc. acquired a new stake in GSK in the fourth quarter valued at approximately $390,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in GSK in the fourth quarter valued at approximately $13,730,000. Finally, Brucke Financial Inc. acquired a new stake in GSK in the fourth quarter valued at approximately $465,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on GSK. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Wall Street Zen upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Finally, BNP Paribas began coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat, GSK has an average rating of "Moderate Buy" and a consensus target price of $40.58.

GSK Stock Performance

Shares of GSK stock traded up $1.03 on Friday, reaching $41.03. The stock had a trading volume of 7,371,682 shares, compared to its average volume of 4,872,127. The business's 50-day moving average price is $37.29 and its two-hundred day moving average price is $36.11. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.01. The stock has a market cap of $84.65 billion, a P/E ratio of 25.81, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The business had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. GSK's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.43 earnings per share. On average, sell-side analysts forecast that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be paid a dividend of $0.4216 per share. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.11%. The ex-dividend date of this dividend is Friday, May 16th. GSK's dividend payout ratio is presently 86.60%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.